share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer WAGNER CHARLES F JR

SEC announcement ·  May 31 04:11
Summary by Futu AI
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,250 shares of common stock on May 28, 2024. The transaction was executed at a price of $454.79 per share, resulting in a total sale value of approximately $1.48 million. Following the sale, Wagner's direct holdings in the company amount to 50,387 shares. The sale took place through an open market transaction, indicating a standard practice of stock disposal by company insiders.
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,250 shares of common stock on May 28, 2024. The transaction was executed at a price of $454.79 per share, resulting in a total sale value of approximately $1.48 million. Following the sale, Wagner's direct holdings in the company amount to 50,387 shares. The sale took place through an open market transaction, indicating a standard practice of stock disposal by company insiders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.